Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, SYRS is expected to report 3Q20 loss of $ 0.38 per share from revenue of $ 2.54 million.
For the full year, analysts anticipate top line of $ 10.62 million, while looking forward to loss of $ 1.53 per share bottom line.
Previous Quarter Performance
Syros Pharmaceuticals, Inc. announced loss for the second quarter of $ 0.38 per share, from the revenue of $ 3.19 million. The quarterly revenues increased 593.48 percent compared with the same quarter last year. Street analysts expected Syros Pharmaceuticals, Inc. to report loss of $ 0.40 per share on revenue of $ 1.90 million for the second quarter. The bottom line results beat street analysts by $ 0.02 or 5.00 percent, at the same time, top line results outshined analysts by $ 1.29 million or 67.89 percent.
Stock Performance
Shares of Syros Pharmaceuticals, Inc. traded up $ 0.68 or 8.97 percent on Wednesday, reaching $ 8.26 with volume of 796.80 thousand shares. Syros Pharmaceuticals, Inc. has traded high as $ 8.80 and has cracked $ 8.16 on the downward trend
The closing price of $ 8.26, representing a 77.93 % increase from the 52 week low of $ 4.26 and a 48.4 % decrease over the 52 week high of $ 14.69.
The company has a market capital of $ 378.00 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Syros Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.syros.com
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd.
